Andrea Kwa, Pharm.D1, Juraj Sprung, M.D., Ph.D.2, Michael Van Guilder, Ph.D3., Roger W. Jelliffe, M.D.3 A Population Model of Epidural Lidocaine
|
R.R. Press(1), B.A. Ploeger(2,3), J. den Hartigh(1), R.J.H.M. van der Straaten(1), J. van Pelt(1), M.Danhof(2,3), J.H. de Fijter(1), H.J. Guchelaar(1). Dose prediction of tacrolimus in de novo kidney transplant patients with population pharmacokinetic modelling.
|
Neil Benson1, Nelleke Snelder2, Bart Ploeger2 , Carolyn Napier1, Harriet Sale1 and Piet van der Graaf1 Utility of a mixed effects approach to defining target binding rate constants.
|
Vincent Buchheit, Marie-Odile Lemarechal, Caterina Ferioli, Aurelie Gautier, Gregory Pinault, Kathy Chen*, Goonaseelan (Colin) Pillai, Jean-Louis Steimer A dedicated SAS Programming Group working in a pharmaceutical Modeling & Simulation organization - Current role, experience and prospects
|
Viera Lukacova, Walter S. Woltosz, Michael B. Bolger PK/PD modeling of Adinazolam – effect of variability of absorption, PK and PD parameters on variability in PD response
|
C.M.T. Sherwin (1, 2), S. Svahn (3), A.J. Van Der Linden (4), N.J. Medlicott (2), R. Broadbent (1), D.M. Reith (1) A pharmacokinetic/pharmacodynamic model to determine optimal dosing targets for amikacin in neonatal sepsis
|
D. Hirt, F. Batteux, S. Urien, J.P. Richardet, P. Sogni, J. Poupon, A. Laurent, S. Pavlovic, M. Debray, J.M. Treluyer, B. Weill Pharmacokinetic-pharmacodynamic modeling of manganese in patients with acute alcoholic hepatitis after an IV infusion of mangafodipir.
|
Almond L1, Rowland Yeo K1, Howgate EM1, Tucker GT1,2, Rostami-Hodjegan A1,2 Mechanistic Prediction of HIV Drug-Drug Interactions in Virtual Populations from in vitro Enzyme Kinetic Data: Ritonavir and Saquinavir.
|
L. McFadyen (1), P. Jacqmin (2), J. Wade (2), B. Weatherley (1) Maraviroc Exposure Response Analysis: Phase 3 Antiviral Efficacy in Treatment Experienced HIV+ Patients
|
Anthe S. Zandvliet (1), Jan H.M. Schellens (2,3), William Copalu (4), Jantien Wanders (4), Jos H. Beijnen (1,2), Alwin D.R. Huitema (1) Dose individualization of indisulam to reduce the risk of severe myelosuppression
|
M.C. Peterson(1), M.M. Riggs(2) Calcium Homeostasis and Bone Remodeling: Development of an Integrated Model for Evaluation and Simulation of Therapeutic Responses to Bone-Related Therapies
|
J. Grevel1, E. Fuseau1, C. Crepin1, M. Vernaz-Gris1, M. Marchand1, D. Huntjens2 Evaluation of the population pharmacokinetic properties of lidocaine and its metabolites, MEGX, GX, and 2,6-xylidine, after application of lidocaine 5% medicated plaster.
|